Small Molecules

20 March 2013

DART Therapeutics Develops Drug Candidate for Duchenne Muscular Dystrophy

19 March 2013

Upsher-Smith Presents Favorable Phase I Data For USL261, A Novel Formulation Of Intranasal Midazolam, At 65th Annual Meeting Of The American Academy Of Neurology

19 March 2013

Safinamide Phase III MOTION and SETTLE study results presented at 2013 American Academy of Neurology (AAN) Annual Meeting

19 March 2013

InSite Vision Announces Positive Phase 3 Results for BromSite (ISV-303) for the Reduction of Inflammation and Pain after Cataract Surgery

19 March 2013

Boehringer Ingelheim and Lilly initiate MARLINA clinical trial to evaluate use of Trajenta (linagliptin) in patients with type 2 diabetes and albuminuria

18 March 2013

New Study of Cialis (tadalafil) Tablets Co-administered with Finasteride Meets Primary Endpoint in Men with Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia

18 March 2013

R-Tech Ueno: Start of the Patient Enrollment of a Phase 3 Clinical Study of Unoprostone (Development Code UF-021) Ophthalmic Solution for the Treatment of Retinitis Pigmentosa

18 March 2013

Trimel Reports Positive CompleoTRT(TM) Phase III Results for Secondary Efficacy and Safety Endpoints

18 March 2013

Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis

18 March 2013

MethylGene Reports Results of Phase II Trial of MGCD290

18 March 2013

TheraVida Presents Positive Phase 2 Data for Tolenix (THVD-201) in Patients with Overactive Bladder at the 28th Annual Congress of the European Urological Association

16 March 2013

AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause

16 March 2013

Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer

16 March 2013

Daiichi Sankyo Announces Positive Phase 3 Study Results (PRASFIT-ACS) for Prasugrel in Japanese Patients with Acute Coronary Syndrome Undergoing PCI

14 March 2013

Daiichi Sankyo Announces Results of PRASFIT-Elective Study Regarding Use of Prasugrel in Elective Patients with Stable Angina and Chronic Myocardial Infarction Undergoing PCI

14 March 2013

Neos Therapeutics, Inc. Announces FDA Accepts NDA Filing for Extended Release Amphetamine Polistirex for the Once-Daily Treatment of ADHD

14 March 2013

Enobosarm Phase 2 Trial for Muscle Wasting and Physical Function in Patients with Cancer Published in The Lancet Oncology

13 March 2013

Trophos launches first study of olesoxime in Multiple Sclerosis patients

13 March 2013

N30 Pharmaceuticals Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis

13 March 2013

Astellas Pharma Inc.: Submits Application for Marketing Approval of Ipragliflozin (ASP1941), SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan

13 March 2013

Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis

12 March 2013

Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation

12 March 2013

Merck Provides Update on IMPROVE-IT Trial

12 March 2013

Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat

12 March 2013

ANAVEX 2-73 restores mitochondrial functionality, blocks cell death and oxidative stress, preventing onset of Alzheimer’s disease

12 March 2013

Radius Health Completes Enrollment for Phase 3 Study of Bone-Building Osteoporosis Drug

11 March 2013

New trial results support treatment with Inspra (eplerenone) within first 24 hours of symptoms, in addition to standard therapy, in patients with acute STEMI without heart failure

11 March 2013

Moberg Derma Discontinues Clinical Development of Limtop

11 March 2013

The Medicines Company’s Intravenous Cangrelor Demonstrates 22% Reduction in Ischemic Events Compared to Oral Clopidogrel

11 March 2013

Gilead’s Ranexa Reduces Angina Frequency in Study of Chronic Angina Patients With Type 2 Diabetes

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

PD-1 Agonists Pipeline Review

c-Met-Targeted Antibody Therapy Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists